US7045624B2 - Compounds and their uses - Google Patents

Compounds and their uses Download PDF

Info

Publication number
US7045624B2
US7045624B2 US10/664,367 US66436703A US7045624B2 US 7045624 B2 US7045624 B2 US 7045624B2 US 66436703 A US66436703 A US 66436703A US 7045624 B2 US7045624 B2 US 7045624B2
Authority
US
United States
Prior art keywords
hydroxy
groups
amino
alkyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/664,367
Other versions
US20040067970A1 (en
Inventor
Alison Jane Foster
Cornelius Paul Erik Van Der Logt
Erwin Werner Tareilus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conopco Inc
Original Assignee
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conopco Inc filed Critical Conopco Inc
Assigned to CONOPCO, INC. reassignment CONOPCO, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOSTER, ALISON JAYNE, VAN DER LOGT, CORNELIS PAUL ERIK, TAREILUS, ERWIN WERNER
Publication of US20040067970A1 publication Critical patent/US20040067970A1/en
Priority to US11/328,534 priority Critical patent/US20060106217A1/en
Application granted granted Critical
Publication of US7045624B2 publication Critical patent/US7045624B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A23L27/204—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/20—Synthetic spices, flavouring agents or condiments
    • A23L27/205—Heterocyclic compounds
    • A23L27/2054—Heterocyclic compounds having nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24—Thermal properties
    • A61K2800/244—Endothermic; Cooling; Cooling sensation

Definitions

  • the invention relates to compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs.
  • Tetrahydropyrimidine-2-one compounds are known to be useful in pharmaceutical preparations.
  • U.S. Pat. No. 3,821,221 discloses a number of such compounds, and their effect as central nervous system stimulants or depressants. The compounds are said to be of value for therapeutic applications as potential psychotropic drugs.
  • icilin also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one
  • icilin also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one
  • menthol (2-isopropyl-5-methyl-cyclohexanol), which has been extensively applied as an additive in, for example, foodstuffs and oral hygiene products. It is used primarily because it elicits a sensation of coolness in the mouth, and because it has a pleasing mint flavour and odour.
  • the cooling effect of menthol is due to the action of menthol on the nerve endings of the human body which detect hot and cold stimuli. In particular, menthol is believed to activate cold receptors on nerve endings.
  • the use of menthol is limited by its strong minty smell and relative volatility.
  • icilin was capable of producing the same cooling effect as menthol.
  • Icilin has a number of advantages over menthol, for example it is more potent, and has a lower acute toxicity, due to its lack of anaesthetic properties. Icilin was considered to be a particularly useful compound for pharmacological applications because it lacks the flavour and odour of menthol and is not readily absorbed through the skin.
  • icilin has not been disclosed as a replacement for menthol for non-pharmaceutical applications.
  • R 1 and R 2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R 1 is 2-hydroxyphenyl, R 2 is other than 3-nitrophenyl.
  • X is a hydrogen or halogen atom, or an alkyl or alkoxy group
  • Y is hydroxy or alkoxy
  • n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy.
  • a third embodiment of the invention provides a composition comprising a compound of formula [I]:
  • R 1 and R 2 ar independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups.
  • a fourth embodiment of the present invention provides a method of imparting a cooling sensation to a human comprising administering, preferably orally, to said human, a compound according to Formula [I]:
  • R 1 and R 2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R 1 is 2-hydroxyphenyl, R 2 is other than 3-nitrophenyl.
  • alkyl represents a linear or cyclic saturated hydrocarbon which may be straight-chain or branched, and preferably contains up to 20 carbon atoms.
  • alkenyl represents a linear or cyclic, straight-chain or branched unsaturated hydrocarbon which preferably contains up to 20 carbon atoms.
  • an alkyl group is linear, it preferably contains from 1 to 10, more preferably from 1 to 6 carbon atoms. Suitable examples include methyl, ethyl, propyl, butyl, pentyl and hexyl, and isomers thereof.
  • a C 4 group can be present in the form of n-butyl, iso-butyl, sec-butyl or tert-butyl.
  • an alkyl group is cyclic, it preferably contains from 5 to 10 carbon atoms, and may be, for example, cyclopentyl, cyclohexyl, cycloheptyl, decalin or adamantyl.
  • Alkoxy and alkylthio represent alkyl groups linked by an oxygen atom or a sulphur atom respectively, with the alkyl portion being as defined above.
  • Haloalkyl represents an alkyl group as defined above substituted by at least one halogen atom.
  • the alkyl group comprises 1 to 6 carbon atoms, and it is preferably substituted by 1 to 6 halogen atoms, more preferably by 1 to 3 halogen atoms.
  • Typical examples include methyl, ethyl and propyl groups substituted by 1 to 6 halogen atoms selected from chlorine, bromine and fluorine. Methyl groups substituted by 1 to 3 of these halogen atoms are preferred, for example trifluoromethyl and trichloromethyl.
  • Aryl represents a hydrocarbon comprising at least one aromatic ring, and may contain from 5 to 18, preferably from 6 to 14, more preferably from 6 to 10, and most preferably 6 carbon atoms.
  • Typical aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenylenyl, and fluorenyl groups.
  • Particularly preferred aryl groups include phenyl, naphthyl and fluorenyl, with phenyl being most preferable.
  • Aryloxy and arylthio represent aryl groups linked by an oxygen atom or a sulphur atom respectively, with the aryl portion being as defined above.
  • Amino represents a group having the general formula —NR′R′′ where R 40 and R′′ are independently selected from hydrogen atoms and alkyl groups, When R′ and R′′ are alkyl groups they preferably contain from 1 to 10, more preferably from 1 to 4, carbon atoms.
  • Possible amino groups include —NH 2 , methyl amino (i.e. —NHMe), ethyl amino, propyl amino, butyl amino, sec-butyl amino, tert-butyl amino, pentyl amino, hexyl amino, heptyl amino, octyl amino, stearyl amino, dimethyl amino (i.e.
  • Siloxy represents a group of general formula —OSiR 3 , where each R group is independently selected from the group consisting of a hydrogen atom and an alkyl group.
  • the alkyl group preferably has from 1 to 6, more preferably 1 to 4, carbon atoms
  • ester also known as alkoxycarbonyl
  • R is a hydrogen atom or an alkyl group.
  • the alkyl group has from 1 to 6, more preferably from 1 to 4, carbon atoms.
  • heterocyclic represents groups having between 3 and 20, more preferably between 3 and 10, carbon atoms and having one or more 4, 5, 6 or 7 member saturated or unsaturated rings containing 1, 2 or 3 oxygen, nitrogen or sulphur atoms.
  • Heterocyclic groups containing saturated rings include groups based on pyrrolidine, piperidine, tetrahydro-thiophene, dithiolane, oxathiolane, oxazolidine, oxazinane, oxathiane, tetrahydro-thiopyran, tetrahydro-pyran, dioxolane, dioxane, thiazinane, dithiane, thiazolidine, imidazolidine, hexahydro-pyrimidine and tetrahydro-furan.
  • Heterocyclic groups containing aromatic rings include thienyl, benzothienyl, naphthothienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbonlinyl, phenanthridinyl, acridinyl, perimidinyl, perimidinyl,
  • halogen represents any halogen atom selected from fluorine, chlorine, bromine and iodine, with fluorine and chlorine being preferred.
  • the substituent groups may include halogen atoms, hydroxy, thiol, cyano, amino, silyl, nitro, alkyl, haloalkyl, cycloalkyloxy, alkoxy, haloalkoxy, alkoxycarbonyl, carboxyl, carbonyl, alkanoyl, alkylthio, alkylsulphinyl, sulphinyl, alkylsulphonyl, sulphonato, alkylsulphonato, aryl, arylalkyl, alkaryl, aryloxy, arylsulphinyl, arylsulphonyl, arylsulphonato, sulphonamide, carbamoyl, carbamido, alkylamido, alkenyl, alkenyloxy and alkynyl, as well as heterocyclic groups.
  • the preferred optional substituents are halogen atoms, and nitro, hydroxy, alkyl, haloalkyl, alkoxy and carboxy groups.
  • the optional substituent is an alkyl, haloalkyl or alkoxy group
  • the alkyl portion of the substituent preferably contains from 1 to 6 carbon atoms, and is preferably linear.
  • Particularly preferred optional substituents are chlorine atoms, and nitro, hydroxy, methyl, ethyl, tertiary butyl and methoxy groups.
  • the compounds and compositions disclosed in the present invention have the ability to produce a cooling sensation when in contact with the skin and/or mucosal membrane of a human or animal body.
  • a “cooling sensation” as used throughout is thus Intended to mean any sensation of coolness which is perceived by human or animal body.
  • Such a cooling sensation is analogous to the sensation produced by compounds such as menthol, and/or the sensation elicited when cold-sensitive receptors, such as those identified in McKemy et al, Nature, Vol. 416, 2002, 52–58, are stimulated.
  • a cooling sensation is desirable in many different applications.
  • the compounds and compositions of the invention have applications in a number of personal hygine, oral hygiene and food product compositions.
  • Personal hygiene applications include lotions, shaving cream, post shaving preparations, shampoos, conditioners, facial cleansers, soaps, bath oils and foams, antiperspirants, deodorants.
  • Oral hygiene applications include toothpastes, mouthwashes, dental floss, chewing gum and breath fresheners.
  • Foodstuff applications include beverages, spreads, ice-creams and confectionery. Possible other applications where a cooling sensation may be desirable include pharmaceutical products (for example chewable pharmaceutical products, or throat lozenges), tobacco products, insect repellents and cosmetics.
  • a first embodiment of the invention provides the use of a compound of Formula [I] on order to produce a cooling sensation with the proviso that when R 1 is 2-hydroxyphenyl, R 2 is other than 3-nitrophenyl.
  • preferred R 1 groups include optionally substituted alkyl or aryl groups.
  • the alkyl group can be a linear group such as a C 1-10 aliphatic chain, or a cyclic group, such as a C 3-10 cyclic hydrocarbon. It is preferred that R 1 is an optionally substituted aryl or cyclic hydrocarbon group, such as a phenyl or cyclohexyl group.
  • the preferred R 2 groups include hydrogen atoms, or optionally substituted alkyl or aryl groups.
  • the R 2 group can be a linear, aliphatic chain, or a cyclic hydrocarbon, as for R 1 .
  • the preferred groups are optionally substituted aryl and cyclic hydrocarbon groups, with phenyl and cyclohexyl being particularly favoured.
  • each X and Y is independently a halogen atom or an alkyl, alkenyl, haloalkyl, alkoxy, hydroxy, thiol, carboxy, nitro, sulphonamide, sulphonato, sulphonyl, alkoxycarbonyl, carbonyl or amino group, and m and n are independently 0, 1, 2 or 3, with the proviso that when n is 1, m is 1 and Y is a hydroxy group in the ortho position, X is other than a nitro group in the meta position.
  • substituent X or Y groups contain an alkyl portion (e.g. the alkyl portion of haloalkyl), this alkyl portion preferably contains from 1 to 6 carbon atoms. In the case of an alkenyl group, this preferably contains from 2 to 6 carbon atoms.
  • X can be selected from any of the groups listed above, with hydrogen and halogen atoms, and nitro, hydroxy, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxy groups being preferred.
  • the number of X substituents can vary between 0 and 3, and the point of substitution of the phenyl ring may also be varied. It is preferred that there is a single substituent on the phenyl ring, i.e. where m is 1. In this case the substituent can be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule containing the cyclic urea group. The optimal point of attachment will depend on a number of factors, such as the nature of the substituent and its electron-donating or electron-withdrawing effect. Particularly useful compounds include those where the substituent is present in the meta position.
  • Y can be selected from any of the groups listed above, with hydrogen, hydroxy, C 1-6 alkyl, C 1-6 haloalkyl and C 1-6 alkoxy groups being preferred.
  • the number of Y substituents can vary between 0 and 3, and the point of substitution of the phenyl ring may also be varied. It is preferred that there is a single Y substituent (i.e. where n is 1), which may be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule containing the cyclic urea group.
  • Particularly useful compounds include those where the single Y substituent is present in the ortho position.
  • a particularly preferred compound in accordance with the first embodiment of the invention is one according to general formula [III]:
  • X and Y are independently selected from a halogen atom or an alkyl, alkenyl, haloalkyl, alkoxy, hydroxy, thiol, carboxy, nitro or amino group, with the proviso that when Y is a hydroxy group, X is other than a nitro group. It is preferred that X is a hydrogen or halogen atom, or a nitro, hydroxy, C 1-6 alkyl or C 1-6 alkoxy group. Particularly preferred groups include halogen atoms, and methyl, ethyl, methoxy and ethoxy groups. The preferred halogen atom is chlorine.
  • Preferred compounds include 1-(2′-methoxyphenyl)-4-(3′′-nitrophenyl-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3′′-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methoxyphenyl-4-(3′′-chlorophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3′′-chlorophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methylphenyl)-4-(3′′-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methoxyphenyl-4-(3′′-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one
  • the compounds may be used alone, or in a composition in combination with another substance or substances such as a carrier.
  • additional substances such as a carrier.
  • the nature of these additional substances, and the relative proportions of components of the composition will depend on a number of factors, such as the specific use for which the composition is employed.
  • the compositions may be used in a variety of applications, such as those discussed above. Particularly preferred uses include personal hygiene products such as deodorant, shower gel and skin cream; oral hygiene products such as toothpastes and mouthwashes; and foodstuffs, such as beverages, ice-creams, confectionery and spreads.
  • the second embodiment of the invention encompasses compounds of general formula [IV] recited above, or a salt thereof, wherein X is a hydrogen or halogen atom, or a hydroxy, nitro, alkyl or alkoxy group; Y is hydrogen, hydroxy, haloalkyl, nitro or alkoxy, and n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy. It is preferred that when n is 1 and Y is hydroxy, X is not a halogen atom. According to one aspect of this embodiment, it is preferred that when n is 1 and Y is hydroxy, X is alkyl or hydroxy. Particularly preferred in this aspect is where Y is hydroxy.
  • Y is haloalkyl, particularly when Y is nitro.
  • a particularly preferred haloalkyl is halomethyl, most preferably trifluoromethyl.
  • the number of Y substituents may vary between 0 and 3, and the substituents can be present in any position. However, it is preferred that there is a single Y substituent, i.e. where n is 1. This substituent may be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule.
  • the optimal position of the substituent will depend on a number of factors, such as the nature of the substituent and its electron-donating or electron-withdrawing effect. The ortho position is preferred.
  • particularly preferred compounds in accordance with the second embodiment are those according to the general formula [V]:
  • Y is a hydroxy group or a methoxy group.
  • X is preferably a hydrogen or halogen atom, or a hydroxy, C 1-6 alkyl or C 1-6 alkoxy group, providing that where Y is hydroxy, X is alkyl or hydroxy.
  • Particularly preferred X groups include halogen atoms, and methyl, ethyl, methoxy and ethoxy groups. Chlorine atoms and methoxy groups are most preferred.
  • the compounds of this second embodiment of the invention may be used in a variety of applications, such as those discussed above. In particular they may be used in applications similar to those described above in relation to the first embodiment of the invention, for example in personal hygiene products such as deodorant, shower gel and skin cream; oral hygiene products such as mouthwash and toothpaste; and food products.
  • the compounds may have particularly useful applications in foodstuffs such as beverages, spreads, confectionery and ice-cream.
  • the third embodiment of the invention provides novel compositions comprising compounds of the invention.
  • the compositions can be used for a number of applications where a cooling sensation is desirable.
  • applications may include the fields of personal hygiene products (including lotions, shaving cream, post shaving preparations, shampoos, conditioners, facial cleansers, soaps, bath oils and foams, antiperspirants and deodorants); oral hygiene products (including toothpastes, mouthwashes, dental floss, chewing gum and breath fresheners); food products (including beverages, spreads, ice-creams and confectionery); and other applications where a cooling sensation may be desirable (including pharmaceutical products such as chewable pharmaceutical products or throat lozenges, tobacco products, insect repellents and cosmetics).
  • compositions for use as toothpastes, mouthwashes and food products such as confectionery, beverages, spreads and ice-cream.
  • the specific nature of the composition e.g. the nature of the additional components, the relative proportions of the components and the physical nature of the composition will depend on the particular application.
  • a composition such as a toothpaste, mouthwash or food product composition, comprising a compound of formula [I]:
  • R 1 and R 2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups.
  • the compound of formula [I] is other than a compound where R 1 is 2-hydroxyphenyl and R 2 is 3-nitrophenyl.
  • the compound of formula [I] can be any compound resulting from a selection of R 1 and R 2 from the list given above. However, preferred compounds are those which have already been discussed in relation to the first embodiment of the invention above.
  • a composition such as a toothpaste, mouthwash or food product composition, comprising a compound of formula [IV] as discussed above in relation to the second embodiment of the invention.
  • the compound which is capable of producing a cooling sensation is preferably present in an amount of from 0.0001% to 3%, eg from 0.001% to 3% by weight, based on the total weight of the composition.
  • An especially preferred range is from 0.0001% to 0.3% by weight.
  • the compound may present in an amount of from 0.0003% to 0.1% or from 0.003% to 0.1%.
  • Dimethylamino-m-chloropropiophenone hydrochloride (74.9 g, 0.30 mol) was dissolved in 50% aqueous ethanol (700 ml) at reflux. 2-Aminophenol (32.9 g, 0.30 mol) was then added and the resulting red solution was refluxed for a further 2 hours. The reaction mixture was allowed to cool to room temperature and then extracted twice with ethyl acetate (2 ⁇ 100 ml). Note that brine was also added at this point to allow the two layers to separate effectively). The organic extracts were combined and an excess of concentrated hydrochloric acid (47 ml) was added. The solution was concentrated in vacuo and then allowed to cool. The precipitate that formed was filtered of, washed with diethyl ether and dried in vacuo to yield a cream powder (38.1 g, 40%).
  • ⁇ -(o-Hydroxyanilino)-m-chloropropiophenone hydrochloride (4.0 g, 0.013 mol) was taken up in acetic acid (50 ml) and the mixture was warmed to 60° C. Potassium cyanate (2.6 g, 0.032 mol) was added and the resulting reaction mixture was kept at 60° C. for a further 30 minutes and then allowed to cool to room temperature. Water (100 ml) was then added and the suspension was extracted with ethyl acetate (3 ⁇ 30 ml) and the combined organic extracts were washed successively with 10% sodium hydroxide solution (100 ml), 10% hydrochloric acid (100 ml) and brine (100 ml). The organic extract was the dried (Na 2 SO 4 ), concentrated in vacuo and allowed to cool overnight. The precipitate that formed was filtered off and washed with diethyl ether to yield a cream powder (1.6 g, 41%).
  • the compounds tested include a number according to the following general formula:
  • the compounds were dissolved in DMSO by ultrasonication to a 0.1 M solution. 5 ⁇ l of this stock was added to 5 mg of cyclodextrin and 5 ml of 140 Na-tyrode, to achieve a 100 ⁇ M final test concentration.
  • Neurons from trigeminal ganglia of Wistar rats were prepared as described in U.S. Pat. No. 5,811,256. After 24 hours of cultivation, the responsiveness of the neurons to different compounds was measured according to the general procedure described by McKemy et al (Nature, Vol. 416, 2002, 52–58). The test protocol described by McKemy was modified slightly, by using the fluorescent Ca 2+ indicator Fura-2. Detection of the cellular fluorescence signals was performed by videomicroscopical analysis. The neurons were given a cold stimulus by a thermocoupling device and were subsequently tested for responsiveness to the test compounds by superfusion with solutions containing the test compounds while continuously monitoring the cellular Ca 2+ levels.
  • Compound Activity (% relative to Compound 1) 1 100 2 40 3 35 Menthol (comparative example) 42

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
  • Confectionery (AREA)
  • Seeds, Soups, And Other Foods (AREA)

Abstract

Use of a compound according to Formula [I]:
Figure US07045624-20060516-C00001
or a salt thereof to produce a cooling sensation, wherein R1 and R2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R1 is 2-hydroxyphenyl, R2 is other than 3-nitrophenyl.

Description

FIELD OF THE INVENTION
The invention relates to compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs.
BACKGROUND OF THE INVENTION
Tetrahydropyrimidine-2-one compounds are known to be useful in pharmaceutical preparations. For example, U.S. Pat. No. 3,821,221 discloses a number of such compounds, and their effect as central nervous system stimulants or depressants. The compounds are said to be of value for therapeutic applications as potential psychotropic drugs.
As a result of pharmacological research into these tetrahydropyrimidine-2-one derivatives, it was discovered that icilin (also known as AG-3-5, chemical name 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidine-2-one) produced sensations of coldness when in contact with mucous membranes (nostrils, lips and eyelids) of the researchers, and also when ingested (see Wei et al, J. Pharm. Pharmacol. 1983, 35:110–112).
A known compound for producing a sensation of cold is menthol (2-isopropyl-5-methyl-cyclohexanol), which has been extensively applied as an additive in, for example, foodstuffs and oral hygiene products. It is used primarily because it elicits a sensation of coolness in the mouth, and because it has a pleasing mint flavour and odour. The cooling effect of menthol is due to the action of menthol on the nerve endings of the human body which detect hot and cold stimuli. In particular, menthol is believed to activate cold receptors on nerve endings. However, the use of menthol is limited by its strong minty smell and relative volatility.
It was found that icilin was capable of producing the same cooling effect as menthol. Icilin has a number of advantages over menthol, for example it is more potent, and has a lower acute toxicity, due to its lack of anaesthetic properties. Icilin was considered to be a particularly useful compound for pharmacological applications because it lacks the flavour and odour of menthol and is not readily absorbed through the skin. However, icilin has not been disclosed as a replacement for menthol for non-pharmaceutical applications.
DEFINITION OF THE INVENTION
According to a first embodiment of the invention, there is provided the use of a compound according to Formula [I]:
Figure US07045624-20060516-C00002
or a salt thereof to produce a cooling sensation, wherein R1 and R2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R1 is 2-hydroxyphenyl, R2 is other than 3-nitrophenyl.
According to a second embodiment of the invention, there is provided a compound of formula [IV]:
Figure US07045624-20060516-C00003
or a salt thereof, wherein X is a hydrogen or halogen atom, or an alkyl or alkoxy group; Y is hydroxy or alkoxy; and n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy.
A third embodiment of the invention provides a composition comprising a compound of formula [I]:
Figure US07045624-20060516-C00004
or a salt thereof to produce a cooling sensation, wherein R1 and R2 ar independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups.
A fourth embodiment of the present invention provides a method of imparting a cooling sensation to a human comprising administering, preferably orally, to said human, a compound according to Formula [I]:
Figure US07045624-20060516-C00005
wherein R1 and R2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups, with the proviso that when R1 is 2-hydroxyphenyl, R2 is other than 3-nitrophenyl.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise specified in the following description, alkyl represents a linear or cyclic saturated hydrocarbon which may be straight-chain or branched, and preferably contains up to 20 carbon atoms. Similarly, alkenyl represents a linear or cyclic, straight-chain or branched unsaturated hydrocarbon which preferably contains up to 20 carbon atoms. When an alkyl group is linear, it preferably contains from 1 to 10, more preferably from 1 to 6 carbon atoms. Suitable examples include methyl, ethyl, propyl, butyl, pentyl and hexyl, and isomers thereof. For example, a C4 group can be present in the form of n-butyl, iso-butyl, sec-butyl or tert-butyl. When an alkyl group is cyclic, it preferably contains from 5 to 10 carbon atoms, and may be, for example, cyclopentyl, cyclohexyl, cycloheptyl, decalin or adamantyl.
Alkoxy and alkylthio represent alkyl groups linked by an oxygen atom or a sulphur atom respectively, with the alkyl portion being as defined above.
Haloalkyl represents an alkyl group as defined above substituted by at least one halogen atom. Preferably the alkyl group comprises 1 to 6 carbon atoms, and it is preferably substituted by 1 to 6 halogen atoms, more preferably by 1 to 3 halogen atoms. Typical examples include methyl, ethyl and propyl groups substituted by 1 to 6 halogen atoms selected from chlorine, bromine and fluorine. Methyl groups substituted by 1 to 3 of these halogen atoms are preferred, for example trifluoromethyl and trichloromethyl.
Aryl represents a hydrocarbon comprising at least one aromatic ring, and may contain from 5 to 18, preferably from 6 to 14, more preferably from 6 to 10, and most preferably 6 carbon atoms. Typical aryl groups include phenyl, naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenylenyl, and fluorenyl groups. Particularly preferred aryl groups include phenyl, naphthyl and fluorenyl, with phenyl being most preferable.
Aryloxy and arylthio represent aryl groups linked by an oxygen atom or a sulphur atom respectively, with the aryl portion being as defined above.
Amino represents a group having the general formula —NR′R″ where R40 and R″ are independently selected from hydrogen atoms and alkyl groups, When R′ and R″ are alkyl groups they preferably contain from 1 to 10, more preferably from 1 to 4, carbon atoms. Possible amino groups include —NH2, methyl amino (i.e. —NHMe), ethyl amino, propyl amino, butyl amino, sec-butyl amino, tert-butyl amino, pentyl amino, hexyl amino, heptyl amino, octyl amino, stearyl amino, dimethyl amino (i.e. —NMe2), diethyl amino, dipropyl amino, dibutyl amino, disec-butyl amino, ditert-butyl amino, dipentyl amino, dihexyl amino, diheptyl amino, dioctyl amino and distearyl amino. Mixed dialkyl amino groups (i.e. where R′ and R″ are different) are also possible.
Siloxy represents a group of general formula —OSiR3, where each R group is independently selected from the group consisting of a hydrogen atom and an alkyl group. The alkyl group preferably has from 1 to 6, more preferably 1 to 4, carbon atoms
The term ester (also known as alkoxycarbonyl) represents a group of formula —C(O)OR where R is a hydrogen atom or an alkyl group. Preferably the alkyl group has from 1 to 6, more preferably from 1 to 4, carbon atoms.
The term heterocyclic represents groups having between 3 and 20, more preferably between 3 and 10, carbon atoms and having one or more 4, 5, 6 or 7 member saturated or unsaturated rings containing 1, 2 or 3 oxygen, nitrogen or sulphur atoms. Heterocyclic groups containing saturated rings include groups based on pyrrolidine, piperidine, tetrahydro-thiophene, dithiolane, oxathiolane, oxazolidine, oxazinane, oxathiane, tetrahydro-thiopyran, tetrahydro-pyran, dioxolane, dioxane, thiazinane, dithiane, thiazolidine, imidazolidine, hexahydro-pyrimidine and tetrahydro-furan.
Heterocyclic groups containing aromatic rings (heteroaryl groups) include thienyl, benzothienyl, naphthothienyl, thianthrenyl, furyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathinyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbonlinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenazinyl, isothiazolyl, phenothiazinyl, isoxazolyl, furazanyl, quinoxalynyl, quinazolynyl, pylazinyl, acrydinyl, phenadinyl, furluryl, isochiazolyl, isoquixazolyl, phenoquisadinyl, benzthiazolyl, benzoxazylyl, benzoinidazolyl, pyranthrenyl, oparenyl and phenoxazinyl.
The term halogen represents any halogen atom selected from fluorine, chlorine, bromine and iodine, with fluorine and chlorine being preferred.
Where any of the groups defined above are described as being optionally substituted, the substituent groups may include halogen atoms, hydroxy, thiol, cyano, amino, silyl, nitro, alkyl, haloalkyl, cycloalkyloxy, alkoxy, haloalkoxy, alkoxycarbonyl, carboxyl, carbonyl, alkanoyl, alkylthio, alkylsulphinyl, sulphinyl, alkylsulphonyl, sulphonato, alkylsulphonato, aryl, arylalkyl, alkaryl, aryloxy, arylsulphinyl, arylsulphonyl, arylsulphonato, sulphonamide, carbamoyl, carbamido, alkylamido, alkenyl, alkenyloxy and alkynyl, as well as heterocyclic groups. The preferred optional substituents are halogen atoms, and nitro, hydroxy, alkyl, haloalkyl, alkoxy and carboxy groups. When the optional substituent is an alkyl, haloalkyl or alkoxy group, the alkyl portion of the substituent preferably contains from 1 to 6 carbon atoms, and is preferably linear. Particularly preferred optional substituents are chlorine atoms, and nitro, hydroxy, methyl, ethyl, tertiary butyl and methoxy groups.
The compounds and compositions disclosed in the present invention have the ability to produce a cooling sensation when in contact with the skin and/or mucosal membrane of a human or animal body. A “cooling sensation” as used throughout is thus Intended to mean any sensation of coolness which is perceived by human or animal body. Such a cooling sensation is analogous to the sensation produced by compounds such as menthol, and/or the sensation elicited when cold-sensitive receptors, such as those identified in McKemy et al, Nature, Vol. 416, 2002, 52–58, are stimulated.
A cooling sensation is desirable in many different applications. For example, the compounds and compositions of the invention have applications in a number of personal hygine, oral hygiene and food product compositions.
Personal hygiene applications include lotions, shaving cream, post shaving preparations, shampoos, conditioners, facial cleansers, soaps, bath oils and foams, antiperspirants, deodorants. Oral hygiene applications include toothpastes, mouthwashes, dental floss, chewing gum and breath fresheners. Foodstuff applications include beverages, spreads, ice-creams and confectionery. Possible other applications where a cooling sensation may be desirable include pharmaceutical products (for example chewable pharmaceutical products, or throat lozenges), tobacco products, insect repellents and cosmetics.
As stated above, a first embodiment of the invention provides the use of a compound of Formula [I] on order to produce a cooling sensation with the proviso that when R1 is 2-hydroxyphenyl, R2 is other than 3-nitrophenyl. In this embodiment, it has been found that preferred R1 groups include optionally substituted alkyl or aryl groups. The alkyl group can be a linear group such as a C1-10 aliphatic chain, or a cyclic group, such as a C3-10 cyclic hydrocarbon. It is preferred that R1 is an optionally substituted aryl or cyclic hydrocarbon group, such as a phenyl or cyclohexyl group.
The preferred R2 groups include hydrogen atoms, or optionally substituted alkyl or aryl groups. Again, the R2 group can be a linear, aliphatic chain, or a cyclic hydrocarbon, as for R1. The preferred groups are optionally substituted aryl and cyclic hydrocarbon groups, with phenyl and cyclohexyl being particularly favoured. Alternatively, it may be desirable to replace these cyclic groups with other groups, such as a hydrogen atom, a straight chain alkyl group (e.g. a C3-10 alkyl group) or a branched chain alkyl group (e.g. a tertiary butyl group).
A subset of particularly preferred compounds in the first embodiment are those according to general formula [II]:
Figure US07045624-20060516-C00006
wherein the or each X and Y is independently a halogen atom or an alkyl, alkenyl, haloalkyl, alkoxy, hydroxy, thiol, carboxy, nitro, sulphonamide, sulphonato, sulphonyl, alkoxycarbonyl, carbonyl or amino group, and m and n are independently 0, 1, 2 or 3, with the proviso that when n is 1, m is 1 and Y is a hydroxy group in the ortho position, X is other than a nitro group in the meta position. Where the substituent X or Y groups contain an alkyl portion (e.g. the alkyl portion of haloalkyl), this alkyl portion preferably contains from 1 to 6 carbon atoms. In the case of an alkenyl group, this preferably contains from 2 to 6 carbon atoms.
X can be selected from any of the groups listed above, with hydrogen and halogen atoms, and nitro, hydroxy, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxy groups being preferred. The number of X substituents can vary between 0 and 3, and the point of substitution of the phenyl ring may also be varied. It is preferred that there is a single substituent on the phenyl ring, i.e. where m is 1. In this case the substituent can be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule containing the cyclic urea group. The optimal point of attachment will depend on a number of factors, such as the nature of the substituent and its electron-donating or electron-withdrawing effect. Particularly useful compounds include those where the substituent is present in the meta position.
Similarly, Y can be selected from any of the groups listed above, with hydrogen, hydroxy, C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxy groups being preferred. The number of Y substituents can vary between 0 and 3, and the point of substitution of the phenyl ring may also be varied. It is preferred that there is a single Y substituent (i.e. where n is 1), which may be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule containing the cyclic urea group. Particularly useful compounds include those where the single Y substituent is present in the ortho position.
Thus, a particularly preferred compound in accordance with the first embodiment of the invention is one according to general formula [III]:
Figure US07045624-20060516-C00007
wherein X and Y are independently selected from a halogen atom or an alkyl, alkenyl, haloalkyl, alkoxy, hydroxy, thiol, carboxy, nitro or amino group, with the proviso that when Y is a hydroxy group, X is other than a nitro group. It is preferred that X is a hydrogen or halogen atom, or a nitro, hydroxy, C1-6 alkyl or C1-6 alkoxy group. Particularly preferred groups include halogen atoms, and methyl, ethyl, methoxy and ethoxy groups. The preferred halogen atom is chlorine.
A number of compounds have been synthesised, and show an ability to elicit a cooling sensation. Preferred compounds include 1-(2′-methoxyphenyl)-4-(3″-nitrophenyl-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methoxyphenyl-4-(3″-chlorophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3″-chlorophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methylphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-methoxyphenyl-4-(3″-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3″-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-hydroxyphenyl)-4-(3″-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-trifluoromethylphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one and 1-(2′-hydroxyphenyl)-4-phenyl-1,2,3,6-tetrahydropyrimidine-2-one. In particular, 1-(2′-hydroxyphenyl)-4-(3″-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-trifluoromethylphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one and 1-(2′-hydroxyphenyl)-4-phenyl-1,2,3,6-tetrahydropyrimidine-2-one have shown good cooling effects.
The compounds may be used alone, or in a composition in combination with another substance or substances such as a carrier. The nature of these additional substances, and the relative proportions of components of the composition will depend on a number of factors, such as the specific use for which the composition is employed. The compositions may be used in a variety of applications, such as those discussed above. Particularly preferred uses include personal hygiene products such as deodorant, shower gel and skin cream; oral hygiene products such as toothpastes and mouthwashes; and foodstuffs, such as beverages, ice-creams, confectionery and spreads.
The second embodiment of the invention encompasses compounds of general formula [IV] recited above, or a salt thereof, wherein X is a hydrogen or halogen atom, or a hydroxy, nitro, alkyl or alkoxy group; Y is hydrogen, hydroxy, haloalkyl, nitro or alkoxy, and n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy. It is preferred that when n is 1 and Y is hydroxy, X is not a halogen atom. According to one aspect of this embodiment, it is preferred that when n is 1 and Y is hydroxy, X is alkyl or hydroxy. Particularly preferred in this aspect is where Y is hydroxy.
In other embodiments it is preferred that Y is haloalkyl, particularly when Y is nitro. A particularly preferred haloalkyl is halomethyl, most preferably trifluoromethyl.
The number of Y substituents may vary between 0 and 3, and the substituents can be present in any position. However, it is preferred that there is a single Y substituent, i.e. where n is 1. This substituent may be present in the ortho, meta or para position, relative to the point of attachment of the phenyl ring to the rest of the molecule. The optimal position of the substituent will depend on a number of factors, such as the nature of the substituent and its electron-donating or electron-withdrawing effect. The ortho position is preferred. Thus, particularly preferred compounds in accordance with the second embodiment are those according to the general formula [V]:
Figure US07045624-20060516-C00008
with Y being as defined above. It is preferred that Y is a hydroxy group or a methoxy group. X is preferably a hydrogen or halogen atom, or a hydroxy, C1-6 alkyl or C1-6 alkoxy group, providing that where Y is hydroxy, X is alkyl or hydroxy. Particularly preferred X groups include halogen atoms, and methyl, ethyl, methoxy and ethoxy groups. Chlorine atoms and methoxy groups are most preferred.
Compounds according to this embodiment which have been shown to exhibit a cooling effect include those listed above in relation to the first embodiment, particularly 1-(2′-hydroxyphenyl)-4-(3″-methoxyphenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-(2′-trifluoromethylphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one, 1-phenyl-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one and 1-(2′-hydroxyphenyl)-4-phenyl-1,2,3,6-tetrahydropyrimidine2-one. Most preferred are 1-(2′-hydroxyphenyl)-4-(3″-methoxyphenyl)1,2,3,6tetrahydropyrimidine-2-one and 1-(2′-trifluoromethylphenyl)-4-(3″-nitrophenyl)-1,2,3,6-tetrahydropyrimidine-2-one.
Again, the compounds of this second embodiment of the invention may be used in a variety of applications, such as those discussed above. In particular they may be used in applications similar to those described above in relation to the first embodiment of the invention, for example in personal hygiene products such as deodorant, shower gel and skin cream; oral hygiene products such as mouthwash and toothpaste; and food products. The compounds may have particularly useful applications in foodstuffs such as beverages, spreads, confectionery and ice-cream.
The third embodiment of the invention provides novel compositions comprising compounds of the invention. The compositions can be used for a number of applications where a cooling sensation is desirable. As discussed above, such applications may include the fields of personal hygiene products (including lotions, shaving cream, post shaving preparations, shampoos, conditioners, facial cleansers, soaps, bath oils and foams, antiperspirants and deodorants); oral hygiene products (including toothpastes, mouthwashes, dental floss, chewing gum and breath fresheners); food products (including beverages, spreads, ice-creams and confectionery); and other applications where a cooling sensation may be desirable (including pharmaceutical products such as chewable pharmaceutical products or throat lozenges, tobacco products, insect repellents and cosmetics).
Particularly preferred are compositions for use as toothpastes, mouthwashes and food products such as confectionery, beverages, spreads and ice-cream. The specific nature of the composition (e.g. the nature of the additional components, the relative proportions of the components and the physical nature of the composition) will depend on the particular application.
In a first aspect of the third embodiment, there is provided a composition, such as a toothpaste, mouthwash or food product composition, comprising a compound of formula [I]:
Figure US07045624-20060516-C00009
or a salt thereof to produce a cooling sensation, wherein R1 and R2 are independently selected from hydrogen or halogen atoms; hydroxy, cyano, nitro, mercapto, carbonyl, sulfone and carboxy groups; or optionally substituted alkyl, alkenyl, alkoxy, alkylthio, aryl, aryloxy, arylthio, amino, siloxy, ester and heterocyclic groups. In this aspect it is preferred that the compound of formula [I] is other than a compound where R1 is 2-hydroxyphenyl and R2 is 3-nitrophenyl.
The compound of formula [I] can be any compound resulting from a selection of R1 and R2 from the list given above. However, preferred compounds are those which have already been discussed in relation to the first embodiment of the invention above.
In a second aspect of this embodiment of the invention, there is provided a composition, such as a toothpaste, mouthwash or food product composition, comprising a compound of formula [IV] as discussed above in relation to the second embodiment of the invention.
In either aspect, the compound which is capable of producing a cooling sensation is preferably present in an amount of from 0.0001% to 3%, eg from 0.001% to 3% by weight, based on the total weight of the composition. An especially preferred range is from 0.0001% to 0.3% by weight. The compound may present in an amount of from 0.0003% to 0.1% or from 0.003% to 0.1%.
The compounds disclosed above in all embodiments of the invention can be made according to a general process shown in Scheme 1:
Figure US07045624-20060516-C00010
The β-amino-ketone compound required in Scheme 1 can be made by any suitable process, for example according to the synthetic route described in Examples 1 and 2 below, or via the synthetic routes disclosed in the examples of U.S. Pat. No. 3,821,221.
Preferred embodiments of the invention will now be described by way of example only. Further modification within the scope of the present invention will be apparent to the person skilled in the art.
EXAMPLES Example 1 Preparation of dimethylamino-m-chloropropiophenone Hydrochloride
To a solution of tetramethyldiaminomethane (15.0 ml, 0.11 mol) in acetonitrile (350 ml) under nitrogen was added dropwise a solution of acetyl chloride (7.8 ml, 0.11 mol) in acetonitrile (7.83 ml) at room temperature. After the addition, stirring was continued for one hour and then 3′-chloroacetophenone (20.0 g, 0.13 mol) was added over 5 minutes. The reaction mixture was refluxed for 2 hours, cooled to room temperature and the white precipitate that formed was filtered off, washed with cold acetonitrile and dried under vacuum (22.9 g, 84%).
Figure US07045624-20060516-C00011
1H NMR (d6-DMSO, 500 MHz)δH 2.80 (6H, s, 2×CH3), 3.39 (2H, t, CH2, 3JHH=7.25 Hz), 3.64 (2H, t, CH2, 3JHH=6.94 Hz), 7.61 (1H, dd, Hc, 3JHcHb=7.89 Hz), 3JHcHb=7.88 Hz, 7.77 (1H, ddd, Hb, 3JHbHc=7.88 Hz, 4JHbHd=2.20 Hz, 4JHbHa=0.94 Hz), 7.97 (1H, ddd, Hd, 3JHdHc=7.88 Hz, 4JHdHb=0.95 Hz, 4JHdHa=1.58 Hz), 8.04 (1H, dd, Ha, 4JHdHa=1.89 Hz, 4JHaHd=1.89 Hz).
Example 2 Preparation of β-(o-hydroxyanilino)-m-chloropropiophenone Hydrochloride
Dimethylamino-m-chloropropiophenone hydrochloride (74.9 g, 0.30 mol) was dissolved in 50% aqueous ethanol (700 ml) at reflux. 2-Aminophenol (32.9 g, 0.30 mol) was then added and the resulting red solution was refluxed for a further 2 hours. The reaction mixture was allowed to cool to room temperature and then extracted twice with ethyl acetate (2×100 ml). Note that brine was also added at this point to allow the two layers to separate effectively). The organic extracts were combined and an excess of concentrated hydrochloric acid (47 ml) was added. The solution was concentrated in vacuo and then allowed to cool. The precipitate that formed was filtered of, washed with diethyl ether and dried in vacuo to yield a cream powder (38.1 g, 40%).
Figure US07045624-20060516-C00012
1H NMR (d6-DMSO, 500 MHz) δH 7.92 (1H, m, Hd), 7.90 (1H, dd, Ha, 4JHaHb=1.58 Hz, 4JHaHd=1.26 Hz), 7.75 (1H, ddd, Hb, 3JHbHc=7.89 Hz, 4JHbHd=0.95 Hz, 4JHbHa=1.90 Hz), 7.60 (1H, dd, Hc, 3JHcHb=7.88 Hz, 3JHcHd=8.20 Hz), 7.43 (1H, d, Hj, 3JHjHi=7.89 Hz), 7.19 (1H, t, Hh, 3JHhHi=7.57 Hz, 3JHhHg=7.25 Hz), 7.06 (1H, d, Hg, 3JHgHh=8.20 Hz), 6.88 (1H, ddd, Hi, 3JHiHj=7.56 Hz, 3JHiHj=7.88 Hz, 4JHiHg=1.26 Hz), 3.57 (4H, m, 2×CH2).
Example 3 Preparation of 1-(2′-hydroxyphenyl)-4-(3″-chlorophenyl)-1,2,3,6-tetrahydro-pyrimidine-2-one
β-(o-Hydroxyanilino)-m-chloropropiophenone hydrochloride (4.0 g, 0.013 mol) was taken up in acetic acid (50 ml) and the mixture was warmed to 60° C. Potassium cyanate (2.6 g, 0.032 mol) was added and the resulting reaction mixture was kept at 60° C. for a further 30 minutes and then allowed to cool to room temperature. Water (100 ml) was then added and the suspension was extracted with ethyl acetate (3×30 ml) and the combined organic extracts were washed successively with 10% sodium hydroxide solution (100 ml), 10% hydrochloric acid (100 ml) and brine (100 ml). The organic extract was the dried (Na2SO4), concentrated in vacuo and allowed to cool overnight. The precipitate that formed was filtered off and washed with diethyl ether to yield a cream powder (1.6 g, 41%).
Figure US07045624-20060516-C00013
1H NMR (d6-DMSO, 500 MHz) δH 9.55 (1H, s, NH), 8.70 (1H, s, OH), 7.63 (1H, s, Ha), 7.54 (1H, m, Hc), 7.42 (2H, m, Hb, Hd), 7.18 (1H, d, Hj, 3JHjHi=7.57 Hz), 7.12 (1H, ddd, Hh, 3JHhHi, =7.57 Hz, 3JHhHg=7.88 Hz, 4JHhHj=1.57 Hz), 6.91 (1H, d, Hg, 3JHgHh=8.20 Hz), 6.81 (1H, dd, Hi, 3JHiHj=7.57 Hz, 3JHiHh=7.57 Hz), 5.30 (1H, m, He), 4.25 (2H, m, Hf).
Example 4
The efficacy of different compounds according to the invention was tested in vitro, by exposing cultured neurons to the compounds and monitoring the cellular Ca2+ levels.
The compounds tested include a number according to the following general formula:
Figure US07045624-20060516-C00014
The following specific compounds were tested, along with menthol as a comparative example:
Compound Number X Y
1 NO2 OH
2 CH3 OH
3 Cl OH
The compounds were dissolved in DMSO by ultrasonication to a 0.1 M solution. 5 μl of this stock was added to 5 mg of cyclodextrin and 5 ml of 140 Na-tyrode, to achieve a 100 μM final test concentration.
Neurons from trigeminal ganglia of Wistar rats were prepared as described in U.S. Pat. No. 5,811,256. After 24 hours of cultivation, the responsiveness of the neurons to different compounds was measured according to the general procedure described by McKemy et al (Nature, Vol. 416, 2002, 52–58). The test protocol described by McKemy was modified slightly, by using the fluorescent Ca2+ indicator Fura-2. Detection of the cellular fluorescence signals was performed by videomicroscopical analysis. The neurons were given a cold stimulus by a thermocoupling device and were subsequently tested for responsiveness to the test compounds by superfusion with solutions containing the test compounds while continuously monitoring the cellular Ca2+ levels.
The results were recorded for compounds 1 to 3 and menthol, and are expressed below, as a percentage compared to the activity for compound 1 (icilin).
Compound Activity (% relative to Compound 1)
1 100
2 40
3 35
Menthol (comparative example) 42
It can be seen that compounds according to the invention are effective in producing sensations of coolness when they are brought into contact with cultured neurons. It can be expected that the in vitro efficacy displayed in the above tests will also be achieved when the compounds are brought into contact with the human body (for example, the skin and/or mucosal membranes), thus providing a sensation of coolness.

Claims (9)

1. A compound of formula [IV]:
Figure US07045624-20060516-C00015
or a salt thereof, wherein X is a hydrogen or halogen atom, or a hydroxy, nitro, alkyl or alkoxy group; Y is hydrogen, hydroxy, haloalkyl, nitro or alkoxy; and n is 0, 1, 2 or 3, with the proviso that when n is 1 and Y is hydroxy, X is not nitro.
2. The compound of claim 1, with the proviso that when n is 1 and Y is hydroxy, X is not a halogen atom.
3. The compound of claim 1, wherein Y is hydroxy or alkoxy, with the proviso that when n is 1 and Y is hydroxy, X is alkyl or hydroxy.
4. The compound of claim 1, wherein n is 1.
5. The compound of claim 1, wherein n is 1 and Y is hydroxy.
6. The compound of claim 1, wherein Y is haloalkyl.
7. The compound of claim 6, wherein Y is trifluoromethyl.
8. The compound of claim 1, having the formula [V]:
Figure US07045624-20060516-C00016
wherein Y is C1-6 alkoxy.
9. The compound of claim 1, wherein X is a chlorine atom or a methoxy group.
US10/664,367 2002-09-18 2003-09-17 Compounds and their uses Expired - Fee Related US7045624B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/328,534 US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221697.6A GB0221697D0 (en) 2002-09-18 2002-09-18 Novel compouds and their uses
GB0221697.6 2002-09-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/328,534 Division US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Publications (2)

Publication Number Publication Date
US20040067970A1 US20040067970A1 (en) 2004-04-08
US7045624B2 true US7045624B2 (en) 2006-05-16

Family

ID=9944340

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/664,367 Expired - Fee Related US7045624B2 (en) 2002-09-18 2003-09-17 Compounds and their uses
US11/328,534 Abandoned US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/328,534 Abandoned US20060106217A1 (en) 2002-09-18 2006-01-10 Novel compounds and their uses

Country Status (10)

Country Link
US (2) US7045624B2 (en)
EP (1) EP1546114B1 (en)
JP (1) JP4959939B2 (en)
CN (1) CN100506800C (en)
AU (1) AU2003266321A1 (en)
BR (1) BR0314447A (en)
GB (1) GB0221697D0 (en)
RU (1) RU2334741C2 (en)
WO (1) WO2004026840A1 (en)
ZA (1) ZA200502122B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090514A1 (en) * 2003-07-02 2005-04-28 Mark Reynolds Trp-p8 active compounds and therapeutic treatment methods
US20070142798A1 (en) * 2005-12-16 2007-06-21 The Procter & Gamble Company Disposable absorbent article having serviceable indicia indicating improper fit
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
US20100297038A1 (en) * 2008-01-17 2010-11-25 Givaudan S.A. Benzimidazole Derivatives And Their Use As Cooling Agents
US8558053B2 (en) 2005-12-16 2013-10-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions

Families Citing this family (211)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20070191797A1 (en) * 2006-02-10 2007-08-16 Roe Donald C Absorbent article with sensation member
US20060140984A1 (en) 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
GB0229811D0 (en) * 2002-12-20 2003-01-29 Unilever Plc Compound delivery systems
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
RU2006106920A (en) 2003-08-06 2007-09-20 Синомикс Инк. (Us) T1R HETERO-OLIGOMER TASTE RECEPTORS, CELL LINES THAT EXPRESS THE SPECIFIED RECEPTORS AND TASTE COMPOUNDS
JP2005310310A (en) * 2004-04-23 2005-11-04 Sanyo Electric Co Ltd Tracking balance adjustment device
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
CN102670350A (en) 2005-01-04 2012-09-19 帝国制药美国公司 Cooling topical patch preparation
SG159528A1 (en) * 2005-02-04 2010-03-30 Senomyx Inc Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
US7806880B2 (en) * 2005-03-18 2010-10-05 The Procter & Gamble Company Pull-on wearable article with informational image
US20060264858A1 (en) * 2005-05-20 2006-11-23 Roe Donald C Multi-functional training garment
WO2006131203A1 (en) * 2005-06-10 2006-12-14 Unilever N.V. Oral care composition comprising a 1 , 2 , 3 , 6-tetrahydropyrimidine-2-one cooling agent
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
CA2623545C (en) 2005-10-05 2013-04-09 Cadbury Adams Usa Llc Cooling compositions
RU2407522C2 (en) 2005-10-24 2010-12-27 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Topical analgesic compositions of n,2,3-trimethyl-2-isopropylbutamide and modes of administration thereof
CN101346072B (en) 2005-12-23 2012-09-05 卡夫食品环球品牌有限责任公司 Compositions providing a heating sensation for oral or dermal delivery
CN101346073B (en) 2005-12-23 2013-02-13 卡夫食品环球品牌有限责任公司 Compositions providing a sensation substantially similar to that provided by menthol
US20070233027A1 (en) * 2006-03-31 2007-10-04 The Procter & Gamble Company Absorbent article with sensation member
US8057450B2 (en) * 2006-03-31 2011-11-15 The Procter & Gamble Company Absorbent article with sensation member
US8664467B2 (en) * 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
US8491558B2 (en) * 2006-03-31 2013-07-23 The Procter & Gamble Company Absorbent article with impregnated sensation material for toilet training
DK2010009T3 (en) 2006-04-21 2017-10-02 Senomyx Inc PROCEDURES FOR THE PREPARATION OF SOLID FLAVOR COMPOSITIONS
DE602007004492D1 (en) * 2006-07-14 2010-03-11 Givaudan Sa Benzimidazole as cooling compounds
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US7896858B2 (en) 2006-12-04 2011-03-01 The Procter & Gamble Company Absorbent articles comprising graphics
MX2009006695A (en) * 2006-12-20 2009-09-14 Givaudan Nederland Services B N-substituted-p-menthane-3-carboxamide and uses thereof.
EP1958627A3 (en) 2007-01-04 2010-09-01 Symrise GmbH & Co. KG Use of certain menthyl-3-oxocarbonic acid esters as physiological cooling agents
EP1986473B1 (en) * 2007-04-03 2017-01-25 Tsinghua University Organic electroluminescent device
EP2008530B1 (en) 2007-06-19 2011-01-19 Symrise AG Aroma composition for reducing or suppressing unwanted bitter and astringent impressions
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
ES2395682T3 (en) 2007-08-20 2013-02-14 Symrise Ag Oxalic acid derivatives and their use as physiological refreshing active ingredients
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
CA3044178C (en) * 2008-08-26 2022-03-15 Basf Se Detection and use of aromatic compounds as modulators of the cold-menthol receptor
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2295031B1 (en) 2009-08-05 2018-01-10 Symrise AG Use of pterocarpans as anti-cellulite agents
CN102686205A (en) 2009-10-02 2012-09-19 弗艾米克斯有限公司 Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EP2186506B1 (en) 2009-10-06 2015-09-30 Symrise AG Teeth cleaning compound containing menthol with reduced bitter sensation
US9446267B2 (en) 2009-10-06 2016-09-20 Symrise Ag Products comprising a flavoring agent composition
DE102010002558A1 (en) * 2009-11-20 2011-06-01 Symrise Ag Use of physiological cooling agents and agents containing such agents
US9066880B2 (en) 2010-04-08 2015-06-30 Symrise Ag Use of dihydrodehydrodiisoeugenol and preparations comprising dihydrodehydrodiisoeugenol
US20110293538A1 (en) 2010-05-11 2011-12-01 Symrise Ag Use of rubusoside for reducing or suppressing certain unpleasant taste impressions
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
EP2394703B1 (en) 2010-06-14 2015-12-23 Symrise AG Cooling mixture with reinforced cooling effect of 5-methyl-2-(propan-2-yl)cyclohexyl-N-ethyloxamate
US9029415B2 (en) 2010-06-14 2015-05-12 Symrise Ag Cooling mixtures with an enhanced cooling effect of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate
EP2457554A1 (en) 2010-11-24 2012-05-30 Symrise AG Mixture containing menthol
EP2356977B1 (en) 2011-02-02 2017-12-27 Symrise AG Preparations with wood extracts of Gleditsia
EP2497458A1 (en) 2011-03-08 2012-09-12 B.R.A.I.N. Biotechnology Research And Information Network AG Small molecule modulators of the cold and menthol receptor TRPM8
KR20140045507A (en) 2011-06-24 2014-04-16 암젠 인크 TRPM8 antagonist and its use in therapy
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
WO2013041621A1 (en) 2011-09-20 2013-03-28 Basf Se Low molecular weight modulators of the cold-menthol receptor trpm8 and use thereof
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end
WO2013185843A1 (en) 2012-06-15 2013-12-19 Symrise Ag Cosmetic compositions comprising hyaluronan biosynthesis promoting agents
CN104394718A (en) 2012-07-02 2015-03-04 西姆莱斯股份公司 A method of flavouring a smoking product
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP2695597B1 (en) 2012-08-07 2019-07-24 Symrise AG Cosmetic compositions
EP2745878B1 (en) 2012-12-19 2023-01-25 Symrise AG Cosmetic compositions
EP2948129B1 (en) 2013-01-25 2017-11-22 Wintermute Biomedical, Inc. Therapeutic compounds
EP2764860A1 (en) 2013-02-06 2014-08-13 Basf Sa Cupuassu fatty acid amidoamines and their derivatives
ES2701758T3 (en) 2013-02-27 2019-02-25 Symrise Ag Ginger extract for the protection of stem cells
ES2686046T3 (en) 2013-03-08 2018-10-16 Symrise Ag Antimicrobial compositions
EP2774604B1 (en) 2013-03-08 2017-08-30 Symrise AG Cosmetic compositions
EP2783578A1 (en) 2013-03-26 2014-10-01 Symrise AG Catechin reaction products
EP2789369B1 (en) 2013-04-14 2018-06-06 Symrise AG A composition for lightening skin and hair
EP2807925A1 (en) 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
EP2810934A1 (en) 2013-06-09 2014-12-10 Symrise AG New succinate derivatives
EP2842607B1 (en) 2013-09-02 2018-05-30 Symrise AG A skin and/or hair whitening mixture
US10765621B2 (en) 2013-09-22 2020-09-08 Symrise Ag Extracts of halimione portulacoides and their application
EP2853254B1 (en) 2013-09-26 2017-11-08 Symrise AG A composition for lightening skin and/or hair
EP2859883B1 (en) 2013-10-13 2019-05-15 Symrise AG Active mixtures comprising acylated oligopeptides and troxerutin
EP2862852B1 (en) 2013-10-18 2018-07-04 Symrise AG Urea derivatives for the protection of stem cells
US20160250121A1 (en) 2013-10-29 2016-09-01 Paolo Pertile Use of mono ornithine ketoglutarate (mokg)
ES2643590T3 (en) 2014-03-18 2017-11-23 Symrise Ag Titanium dioxide coated to reduce the effect of skin whitening
EP2932858A1 (en) 2014-04-16 2015-10-21 Symrise AG Homovanillic acid esters, in particular for achieving an impression of heat and/or spiciness
EP2962678A1 (en) 2014-06-30 2016-01-06 Symrise AG Flavour and fragrance compositions comprising acetophenone derivatives
EP3443950A1 (en) 2014-07-30 2019-02-20 Symrise AG A fragrance composition
DE102014015151A1 (en) * 2014-10-13 2016-04-14 Schlenk Metallic Pigments Gmbh PVD metallic effect pigment powder
EP3023090B1 (en) 2014-11-21 2019-08-07 Symrise AG Compositions
EP3045161A1 (en) 2015-01-18 2016-07-20 Symrise AG Active compositions comprising 1,2-hexanediol and 1,2-octanediol
ES2933563T3 (en) 2015-04-16 2023-02-10 Symrise Ag Use of a liposome composition
EP3288534B1 (en) 2015-04-28 2020-09-23 Symrise AG Compositions comprising valerian extracts
US10568852B2 (en) 2015-05-22 2020-02-25 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Combination compositions and their use in methods for treating obesity and obesity-related disorders
EP3097905B1 (en) 2015-05-28 2020-11-04 Symrise AG Cosmetic compositions
CN107922882A (en) 2015-09-08 2018-04-17 西姆莱斯股份公司 spice mixture
CN108366932B (en) 2015-10-28 2022-03-15 西姆莱斯股份公司 Method for inhibiting or masking fishy smell
BR112018007384B1 (en) 2015-11-15 2021-02-17 Symrise Ag. composition obtained by spray drying, cosmetic preparation, skin care composition and use of one or more carrier materials
WO2017097434A1 (en) 2015-12-06 2017-06-15 Symrise Ag A fragrance composition
EP3777981A1 (en) 2015-12-10 2021-02-17 Symrise AG A mixture with stabilized taste and/or odor
EP3390596B1 (en) 2015-12-16 2025-03-05 Symrise AG Use of 4-hydroxyacetophenone to stabilize taste and odor
ES2733201T3 (en) 2015-12-21 2019-11-28 Thiocyn Gmbh Cosmetic composition comprising a combination of active substances
ES2730087T3 (en) 2016-01-13 2019-11-08 Thiocyn Gmbh Composition for hair growth
CN109862875A (en) 2016-03-30 2019-06-07 西姆莱斯股份公司 A kind of active mixture
EP3463580B1 (en) 2016-05-23 2020-03-25 Symrise AG A wheat bran extract in a hair care blend
WO2018036625A1 (en) 2016-08-20 2018-03-01 Symrise Ag A preservative mixture
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
JP6828136B2 (en) 2016-10-11 2021-02-10 シムライズ アーゲー Antibacterial composition
EP3547991A1 (en) 2016-12-02 2019-10-09 Symrise AG Cosmetic blends
CN106619141A (en) * 2016-12-20 2017-05-10 天津盛易联科技股份有限公司 Novel dental restoration product for stomatology and preparation method thereof
WO2018148763A1 (en) 2017-02-13 2018-08-16 Wintermute Biomedical, Inc. Anti-pathogenic therapeutic compositions
IT201700090929A1 (en) 2017-08-07 2019-02-07 Cutech S R L Cosmetic and medical uses of extracts of Coprinus comatus fungus for the regulation of pilo sebaceous unity.
WO2019029808A1 (en) 2017-08-09 2019-02-14 Symrise Ag 1,2-alkanediols and a process for their production
DE202017007679U1 (en) 2017-08-09 2024-03-15 Symrise Ag 1,2-Alkanediols
WO2019037844A1 (en) 2017-08-23 2019-02-28 Symrise Ag Novel compositions of natural butters and uses thereof
ES2957659T3 (en) 2017-08-23 2024-01-23 Symrise Ag Uses of Isochrysis sp extracts
JP7231617B2 (en) 2017-08-31 2023-03-01 ビーエーエスエフ ソシエタス・ヨーロピア Use of physiological cooling active ingredients and compositions containing such active ingredients
EP3687311A1 (en) 2017-09-27 2020-08-05 Symrise AG Amides for generating a trigeminal effect
SMT202200011T1 (en) 2017-09-27 2022-03-21 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
BR112020006732B1 (en) 2017-10-10 2022-08-23 Symrise Ag COMPOSITIONS CONTAINING BENZOIC ACID OR FUROIC ACID DERIVATIVES AND USE OF THE DERIVATIVES FOR EMULSION AND FOAM STABILITY
CA3078909A1 (en) 2017-10-16 2019-04-25 Takasago International Corporation Cool-sensation imparter composition containing 2,2,6-trimethylcyclohexanecarboxylic acid derivative
WO2019080990A1 (en) 2017-10-23 2019-05-02 Symrise Ag Aroma composition
WO2019170222A1 (en) 2018-03-06 2019-09-12 Symrise Ag Encapsulated active substance deposition on hairs and textile
KR102562938B1 (en) 2018-03-08 2023-08-02 시므라이즈 아게 Mixtures containing protein extracts for the treatment of human skin and/or hair
WO2019206404A1 (en) 2018-04-24 2019-10-31 Symrise Ag Core-shell capsules prepared with linear and cyclic aliphatic polyisocyanates
AR117600A1 (en) 2018-06-29 2021-08-18 Incyte Corp FORMULATIONS OF AN AXL / MER INHIBITOR
WO2020015816A1 (en) 2018-07-16 2020-01-23 Symrise Ag Composition for substituting sugar in baked goods
US12193441B2 (en) 2018-08-27 2025-01-14 Symrise Ag Antimicrobial mixtures comprising at least one hydroxyphenone derivative
BR112021004054B1 (en) 2018-09-14 2024-02-06 Symrise Ag COMPOSITION FOR HAIR CARE, ITS USE, METHOD FOR STRENGTHENING AND PROTECTING HAIR AND PRODUCT
WO2020057761A1 (en) 2018-09-20 2020-03-26 Symrise Ag Compositions comprising odorless 1,2-pentanediol
WO2020072479A1 (en) 2018-10-01 2020-04-09 Wintermute Biomedical, Inc. Therapeutic compositions
WO2020069762A1 (en) 2018-10-05 2020-04-09 Symrise Ag A method for fighting female body odors
WO2020088778A1 (en) 2018-11-02 2020-05-07 Symrise Ag A liquid and transparent blend of uv filters
WO2020094244A1 (en) 2018-11-08 2020-05-14 Symrise Ag An antimicrobial surfactant based composition
CN116806825A (en) 2019-01-17 2023-09-29 西姆莱斯股份公司 an antimicrobial mixture
WO2020147977A1 (en) 2019-01-18 2020-07-23 Symrise Ag Combination remedy
BR112021017965A2 (en) 2019-03-11 2021-11-23 Symrise Ag Method for improving the performance of a fragrance or fragrance blend.
BR112021017339B1 (en) 2019-03-12 2024-01-30 Symrise Ag ANTIMICROBIAL MIXTURE, COSMETIC COMPOSITION, PERSONAL CARE COMPOSITION, PHARMACEUTICAL COMPOSITION, DETERGENT COMPOSITION OR FOOD COMPOSITION, AND METHOD OF PREVENTION OR TREATMENT THEREOF
WO2020192865A1 (en) 2019-03-22 2020-10-01 Symrise Ag Plant peptides and their applications
US20220332771A1 (en) 2019-03-22 2022-10-20 Symrise Ag Plant peptides and their applications (ii)
US20230059747A1 (en) 2019-06-13 2023-02-23 Symrise Ag A cooling preparation
WO2021001029A1 (en) 2019-07-02 2021-01-07 Symrise Ag Blend of beeswax and a lactylate ester
JP2022547861A (en) 2019-09-04 2022-11-16 シムライズ アーゲー balm mixture
EP4044993A1 (en) 2019-10-16 2022-08-24 Symrise AG Articles for indirect transfer of cosmetic actives to skin
IL296065A (en) 2020-03-06 2022-10-01 Incyte Corp Combined treatment including axl/mer and pd-1/pd-l1 inhibitors
WO2021228352A1 (en) 2020-05-11 2021-11-18 Symrise Ag A fragrance composition
CN115843240A (en) 2020-05-11 2023-03-24 西姆莱斯股份公司 Solid mucoadhesive compositions
WO2021233973A1 (en) 2020-05-22 2021-11-25 Firmenich Sa Compositions for reducing salty taste and uses thereof
US20230157341A1 (en) 2020-06-03 2023-05-25 Firmenich Sa Compositions for reducing off tastes and uses thereof
MX2022015148A (en) 2020-06-24 2023-01-11 Firmenich & Cie Sweetening compositions and uses thereof.
WO2022013163A1 (en) 2020-07-14 2022-01-20 Firmenich Sa Reduction of undesirable taste notes in oral care products
CN116490265A (en) 2020-08-06 2023-07-25 西姆莱斯股份公司 Biodegradable polyurea/polyurethane microcapsules
CN116322326B (en) 2020-08-06 2025-05-02 西姆莱斯股份公司 Polyurea/polyurethane microcapsules
KR20230044009A (en) 2020-08-06 2023-03-31 시므라이즈 아게 Method for making microcapsules
CN115697082A (en) 2020-09-22 2023-02-03 弗门尼舍有限公司 Wintergreen flavor composition without methyl salicylate
WO2022111793A1 (en) 2020-11-24 2022-06-02 Symrise Ag Medicament for accelerated wound healing
WO2022112432A1 (en) 2020-11-29 2022-06-02 Firmenich Sa Compositions that reduce peroxide off taste and uses thereof
WO2022111829A1 (en) 2020-11-30 2022-06-02 Symrise Ag Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes
WO2022122122A1 (en) 2020-12-08 2022-06-16 Symrise Ag Medicament for fighting inflammatory conditions of human skin (i)
WO2022122140A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising one or more (bio)-alkanediols with active ingredients
WO2022122134A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions with (bio)-alkanediols and cooling agents
WO2022122135A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising (bio)-alkanediols with antimicrobials for product protection
WO2022122131A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising lipophilic compounds and one or more (bio)-alkanediols
CN116490160A (en) 2020-12-09 2023-07-25 西姆莱斯股份公司 A mixture containing 1, 2-alkanediol
WO2022122136A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising one or more (bio)-alkanediols with antioxidants
WO2022122133A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising uv-filters and one or more (bio)-alkanediols
WO2022122137A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising antimicrobials and (bio)-alkanediols for skin protection
WO2022122132A1 (en) 2020-12-09 2022-06-16 Symrise Ag Compositions comprising natural polymers and one or more (bio)-alkanediols
WO2022122138A1 (en) 2020-12-09 2022-06-16 Symrise Ag Multifunctional compound mixtures comprising multiple (bio)-alkanediols
WO2022122167A1 (en) 2020-12-11 2022-06-16 Symrise Ag Medicament for preventing or treating pathologic conditions of human skin (i)
WO2022128054A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin (iv)
WO2022128052A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin
WO2022128050A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
WO2022128048A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for preventing or treating pathologic conditions of human skin
WO2022128057A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for prevention and treatment of collagen degradation in human connecting tissue
WO2022128051A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin (ii)
JP2024503845A (en) 2021-01-13 2024-01-29 フィルメニッヒ インコーポレイテッド Composition that enhances cooling effect
WO2022161593A1 (en) 2021-01-26 2022-08-04 Symrise Ag Medicament for accelerated wound healing
US20240122834A1 (en) 2021-02-12 2024-04-18 Symrise Ag Medicament for prevention and treatment of hyperpigmentation
WO2022214187A1 (en) 2021-04-08 2022-10-13 Symrise Ag An o/w emulsion base and emulsions comprising the same
WO2022218505A1 (en) 2021-04-13 2022-10-20 Symrise Ag A fragrance mixture containing isocitronellol
EP4326251A1 (en) 2021-04-19 2024-02-28 Symrise AG Compositions comprising cannabidiol and, optionally, bisabolol
EP4083050A1 (en) 2021-05-01 2022-11-02 Analyticon Discovery GmbH Microbial glycolipids
US20240238183A1 (en) 2021-05-28 2024-07-18 Firmenich Incorporated Compositions that enhance the cooling effect
CN117693332A (en) 2021-06-24 2024-03-12 弗门尼舍有限公司 Oral care compositions
US20240307279A1 (en) 2021-06-30 2024-09-19 Firmenich Sa Fast drying perfume composition
US20240309301A1 (en) 2021-07-30 2024-09-19 Symrise Ag Biobased Core-Shell Microcapsules
EP4415542A1 (en) 2021-12-23 2024-08-21 Firmenich SA Antimicrobial composition having encapsulated colorant
JP2025505605A (en) 2022-02-02 2025-02-28 シムライズ アーゲー Manufacturing method of microcapsules
WO2023147855A2 (en) 2022-02-02 2023-08-10 Symrise Ag Process for producing microcapsules
WO2024011086A1 (en) 2022-07-07 2024-01-11 Firmenich Incorporated Compositions that enhance the cooling effect
EP4554572A2 (en) 2022-07-11 2025-05-21 Symrise AG Mixtures and uses of (2e)-3-(1,3-benzodioxol-5-yl)-n-phenyl-n-(tetrahydro-3-furanyl)-2-propenamide
WO2024027930A1 (en) 2022-08-05 2024-02-08 Symrise Ag Compositions comprising an antimicrobial boosting agent
WO2024027928A1 (en) 2022-08-05 2024-02-08 Symrise Ag Composition with improved spf and uva photoprotection
CN119744164A (en) 2022-08-05 2025-04-01 西姆莱斯股份公司 Odor and colorant stable compositions
WO2025031562A1 (en) 2023-08-04 2025-02-13 Symrise Ag Mycosporine-like amino acid analogue compounds and use thereof
CN119604267A (en) 2022-08-05 2025-03-11 西姆莱斯股份公司 Compositions with improved SPF and UVA photoprotection
WO2024027931A1 (en) 2022-08-05 2024-02-08 Symrise Ag Odor and colorant stabilized compositions
WO2024027926A1 (en) 2022-08-05 2024-02-08 Symrise Ag Composition comprising a uv-filter stabilizer
CN119604270A (en) 2022-08-05 2025-03-11 西姆莱斯股份公司 Comprising an antimicrobial agent accelerator composition
WO2024028515A1 (en) 2022-08-05 2024-02-08 Symrise Ag Composition comprising a uv-filter stabilizer
WO2024133616A1 (en) 2022-12-21 2024-06-27 Firmenich Sa Oral care compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821221A (en) * 1970-08-25 1974-06-28 Delmar Chem 1,2,3,6-tetrahydropyrimidine-2-one compounds and processes for makingthem
JPH0887120A (en) * 1994-09-19 1996-04-02 Fuji Electric Co Ltd Electrophotographic photoreceptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2174388C2 (en) * 1995-08-29 2001-10-10 В. Ман Филс С.А. Aromatizing and refreshing composition
CA2483090C (en) * 2002-05-02 2011-01-25 Cragmont Pharmaceuticals, Llc Use of therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821221A (en) * 1970-08-25 1974-06-28 Delmar Chem 1,2,3,6-tetrahydropyrimidine-2-one compounds and processes for makingthem
JPH0887120A (en) * 1994-09-19 1996-04-02 Fuji Electric Co Ltd Electrophotographic photoreceptor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Briffa, K. et al., Blowing Hot and Cold, Science, vol. 295; pp. 2227-2228, (2002).
Kim, C-H et al., Synthesis of Pyrimidin-2-one Nucleosides as Acid-Stable Inhibitors of Cytidine Deaminase, J. Med. Chem., 29:1364-1380, (1986).
McKerny, D. et al., Identification of a cold receptor reveals a general role for TRP channels in thermosensation, Nature, vol. 416; pp. 52-58, (2002).
Wei et al, "AG-3-5: A chemical producing sensations of cold", Journal of Pharmacy and Pharmacology (1983), 35(2), 110-112. *
Wei, E.T., et al.; AG-3-5: a chemical producing sensations of cold; J. Pharm. Pharmacol.; 35:110-112 (1983).
www.tocris.com/1531.htm printout-An Activator of the Novel Cold Receptor, CMR1.

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090514A1 (en) * 2003-07-02 2005-04-28 Mark Reynolds Trp-p8 active compounds and therapeutic treatment methods
US7893072B2 (en) 2003-07-02 2011-02-22 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
US20070142798A1 (en) * 2005-12-16 2007-06-21 The Procter & Gamble Company Disposable absorbent article having serviceable indicia indicating improper fit
US8558053B2 (en) 2005-12-16 2013-10-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8697938B2 (en) 2005-12-16 2014-04-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8697937B2 (en) 2005-12-16 2014-04-15 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US9662250B2 (en) 2005-12-16 2017-05-30 The Procter & Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
US20100297038A1 (en) * 2008-01-17 2010-11-25 Givaudan S.A. Benzimidazole Derivatives And Their Use As Cooling Agents

Also Published As

Publication number Publication date
BR0314447A (en) 2005-07-19
AU2003266321A1 (en) 2004-04-08
GB0221697D0 (en) 2002-10-30
ZA200502122B (en) 2006-05-31
CN100506800C (en) 2009-07-01
JP2006512294A (en) 2006-04-13
EP1546114B1 (en) 2015-09-30
CN1694872A (en) 2005-11-09
US20040067970A1 (en) 2004-04-08
EP1546114A1 (en) 2005-06-29
RU2334741C2 (en) 2008-09-27
WO2004026840A1 (en) 2004-04-01
JP4959939B2 (en) 2012-06-27
US20060106217A1 (en) 2006-05-18
RU2005111243A (en) 2005-10-27

Similar Documents

Publication Publication Date Title
US7045624B2 (en) Compounds and their uses
JP3245748B2 (en) P-menthane derivative and cooling sensate containing the same
CA2734682C (en) Detection and use of low molecular-weight modulators of the cold-menthol receptor trpm8
US7030273B1 (en) Compounds with physiological cooling effect
BRPI0616821B1 (en) Method for providing a cooling effect in a product and product having a cooling effect
US20100056636A1 (en) N-Substituted-P-Menthane-3-Carboxamide and Uses Thereof
BRPI0609447A2 (en) refreshing compounds
WO2022171653A1 (en) Organic compounds as trpm8 activators
JP4938680B2 (en) Thienopyrimidine as a coolant
US20060280697A1 (en) Composition
JPH02290827A (en) 1-alkoxy-3-l-menthoxypropane-2-ol, cooling agent and cooling composition containing the same compound
CN114761385B (en) TRPM8 modulators
CA2142671C (en) Composition for enhancing hair growth
BRPI0709393A2 (en) substituted 2-alkoxyphenols compounds, use thereof, method of providing a refreshing effect to the mouth or skin and product containing said compounds
US20210093531A1 (en) Derivatives of menthol and uses thereof
AU2016342264A1 (en) Synthesis of cyclohexane carboxamide derivatives useful as sensates in consumer products
JPH05255186A (en) 3-substituted-p-menthane derivative and cold-sensation agent containing the same derivative
EP0427625B1 (en) Internal salts of 2,4-diamino-6-alkoxy-3-sulphooxypyrmidium hydroxide and their use in the treatment and prevention of hair-loss

Legal Events

Date Code Title Description
AS Assignment

Owner name: CONOPCO, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOSTER, ALISON JAYNE;VAN DER LOGT, CORNELIS PAUL ERIK;TAREILUS, ERWIN WERNER;REEL/FRAME:014241/0108;SIGNING DATES FROM 20030820 TO 20031001

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

OSZAR »